ISBN-13: 9783659815126 / Angielski / Miękka / 2015 / 96 str.
Fibroblast growth factor 23 (FGF-23), is recently discovered phosphaturic substance. It releases from bone osteocytes and plays a key role in the physiological regulation of phosphate metabolism. Excessive action of FGF23 results in several hypophosphatemic diseases characterized by impaired renal tubular phosphate reabsorption. In contrast, deficient action of FGF23 causes familial hyperphosphatemic tumoral calcinosis with enhanced renal tubular phosphate reabsorption. We carried out this study to gain knowledge about the current status of FGF-23 levels in our population and its relationship with serum phosphate; TmP/GFR and dietary phosphate; which has implications for the diagnosis and treatment of phosphate-wasting disorders and may guide us in planning further studies to see its role and implications on vitamin D metabolism.
Fibroblast growth factor 23 (FGF-23), is recently discovered phosphaturic substance. It releases from bone osteocytes and plays a key role in the physiological regulation of phosphate metabolism. Excessive action of FGF23 results in several hypophosphatemic diseases characterized by impaired renal tubular phosphate reabsorption. In contrast, deficient action of FGF23 causes familial hyperphosphatemic tumoral calcinosis with enhanced renal tubular phosphate reabsorption. We carried out this study to gain knowledge about the current status of FGF-23 levels in our population and its relationship with serum phosphate; TmP/GFR and dietary phosphate; which has implications for the diagnosis and treatment of phosphate-wasting disorders and may guide us in planning further studies to see its role and implications on vitamin D metabolism.